Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells

Carcinogenesis

Volumn 24, Issue 11, 2003, Pages 1749-1758

  Chang, Pi Ling ^a   Cao, Minhton ^a   Hicks, Patricia ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLYCOPROTEIN; MESSENGER RNA; OSTEOPONTIN; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR PROMOTER;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SKIN CARCINOGENESIS; SKIN CARCINOMA; TUMOR CELL LINE; TUMOR PROMOTION;

ANIMALS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DEXAMETHASONE; FIBRONECTINS; MICE; OSTEOPONTIN; PRECANCEROUS CONDITIONS; SERUM ALBUMIN, BOVINE; SIALOGLYCOPROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 0242475362     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgg138     Document Type: Article

References (75)

1. Weaver,V.M., Fischer,A.H., Peterson,O.W. and Bissell,M.J. (1996) The importance of the microenvironment in breast cancer progression: recapitulation of mammary tumorigenesis using a unique human mammary epithelial cell model and a three-dimensional culture assay. Biochem. Cell Biol., 74, 833-851.
2. Sanders,R.J., Mainiero,F. and Giancotti,F.G. (1998) The role of integrins in tumorigenesis and metastasis. Cancer Invest., 16, 329-344.
3. Boudreau,N. and Bissell,M.J. (1998) Extracellular matrix signaling: integration of form and function in normal and malignant cells. Curr. Opin. Cell Biol., 10, 640-646.
4. Sternlicht,M.D.. Bissell,M.J. and Werb,Z. (2000) The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene, 19, 1102 1113.
5. Denhardt,D.T., Giachelli,C.M. and Rittling,S.R. (2001) Role of osteopontin in cellular signaling and toxicant injury. Ann. Rev. Pharmacol. Toxicol., 41, 723-749.
6. Patarca,R., Saavedra,R.A. and Cantor,H.(1993) Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol., 13, 225-246.
7. Oates,A.J., Barraclough,R. and Rudland,P.S. (1997) The role of osteopontin in tumorigenesis and metastasis. Invasion Metast., 17, 1-15.
8. Senger,D.R., Perruzzi,C.A. and Papadopoulos,A. (1989) Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res., 9, 1291-1299.
9. Wu,Y., Denhardt,D.T. and Rittling,S.T. (2000) Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br. J. Cancer, 83, 156-163.
10. Feng,F. and Rittling,S.R. (2000) Mammary tumor develpment in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res. Treat., 63, 71-79.
11. Chang,P.L. and Chambers,A.F. (2000) Transforming JB6 cells exhibit enhanced Integrin-mediated adhesion to osteopontin. J. Cell. Biochem., 78, 8-23.
12. Senger,D.R., Perruzzi,C.A., Gracey,C.F., Papadopoulos,A. and Tenen,D.G. (1988) Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res., 48, 5770-5774.
13. Singhal,H., Bautista,D.S., Tonkin,K.S., Omalley,F.P., Tuck,A.B., Chambers,A.F. and Harris,J.F. (1997) Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res., 3, 605-611.
14. Kim,J.H., Skates,S.J., Uede,T., Wong,Kk.K.K., Schorge,J.O., Feltmate,C.M., Berkowitz, R.S., Cramer,D.W. and Mok,S.C. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J. Am. Med. Assoc., 287, 1671-1679.
15. Fedarko,N.S., Jain,A., Karadag,A., Van Eman,M.R. and Fisher,L.W. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 7, 4060-4066.
16. Le,Q.-T., Sutphin,P.D., Raychaudhuri,S., Yu,S.C.T., Terris,D.J., Lin,H.S., Lum,B., Pinto,H.A., Koong,A.C. and Giaccia,A.J. (2003) Identification of osteopontin as a prognostic plasma marker for Head and Neck Squamous Cell Carcinomas. Clin. Cancer Res., 9, 59-67.
17. Furger,K.A., Menon,R.K., Tuck,A.B., Bramwelll,V.H. and Chambers,A.F. (2001) The functional and clinical roles of osteopontin in cancer and metastasis. Curr. Mol. Med., 1, 621-632.
18. Agrawal,D., Chen,T., Irby,R., Quackenbush,J., Chambers,A.F., Szabo,M., Cantor,A., Coppola,D. and Yeatman,T.J. (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst., 94, 513-521.
19. Rudland,P.S., Platt-Higgins,A., El-Tanani,M., De Silva Rudland,S., Barraclough,R., Winstanley,J.H., Howitt,R. and West,C.R. (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res., 62, 3417-3427.
20. Shijubo,N., Kojima,H., Nagata,M., Ohchi,T., Suzuki,A., Abe,S. and Sato,N. (2003) Tumor angiogenesis of non-small cell lung cancer. Microsc. Res. Tech., 60, 186-198.
21. Giordano,T.J., Thomas,D.G., Kuick,R. et al. (2003) Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol., 162, 521-531.
22. Tiniakos,D.G., Yu,H. and Liapis,H. (1998) Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). Hum. Pathol., 29, 1250-1254.
23. Devoll,R.E., Li,W., Woods,K.V., Pinero,G.J., Butler,W.T., Farach-Carson,M.C. and Happonen,R.P. (1999) Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J. Oral Pathol. Med., 28, 97-101.
24. Craig,A.M., Bowden,G.T., Chambers,A.F., Spearman,M.A., Greenberg,A.H., Wright,J.A., McLeod,M. and Denhardt,D.T. (1990) Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Intl. J. Cancer, 46, 133-137.
25. Hashimoto,Y., Tajima,O., Hashiba,H., Nose,K. and Kuroki,T. (1990) Elevated expression of secondary, but not early, responding genes to phorbol ester tumor promoters in papillomas and carcinomas of mouse skin. Mol. Carcinogen., 3, 302-308.
26. Miyauchi,A., Alvarez,J., Greenfield,E.M. et al. (1991) Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J. Biol. Chem., 266, 20369-20374.
27. Grano,M., Zigrino,P., Colucci,S., Zambonin,G., Trusolino,L., Serra,M., Baldini,N., Teti,A., Marchisio,P.C. and Zallone,A.Z. (1994) Adhesion properties and integrin expression of cultured human osteoclast-like cells. Exp. Cell Res., 212, 209-218.
28. Liaw,L., Lindner,V., Schwartz,S.M., Chambers,A.F. and Giachelli,C.M. (1995) Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Cir. Res., 77, 665-672.
29. Hu,D.D., Lin,E.C., Kovach,N.L., Hoyer,J.R. and Smith,J.W. (1995) A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J. Biol. Chem., 270, 26232-26238.
30. van Dijk,S., D'Errico,J.A., Somerman,M.J., Farach-Carson,M.C. and Butler,W.T. (1993) Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment. J. Bone Min. Res., 8, 1499-1506.
31. Nasu,K., Ishida,T., Setoguchi,M., Higuchi,Y., Akizuki,S. and Yamamoto,S. (1995) Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388DI cells. Biochem. J., 307, 257-265.
32. Katagiri,Y.U., Murakami,M., Mori,K., Iizuka,J., Hara,T., Tanaka,K., Jia,W.Y., Chambers,A.F. and Uede,T. (1996) Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins. J. Cell. Biochem., 62, 123-131.
33. Smith,L.L., Cheung,H.K., Ling,L.E., Chen,J., Sheppard,D., Pytela,R. and Giachelli,C.M. (1996) Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin. J. Biol. Chem., 271, 28485-28491.
34. Weber,G.F., Ashkar,S., Glimcher,M.J. and Cantor,H. (1996) Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science, 271, 509-512.
35. Katagiri,Y.U., Sleeman,J., Fujii,H. et al. (1999) CD44 variants but not CD44 s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res., 59, 219-226.
36. Chambers,A.F., Behrend,E.I., Wilson,S.M. and Denhardt,D.T. (1992) Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res., 12, 43-47.
37. Gardner,H.A., Berse,B. and Senger,D.R. (1994) Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9, 2321-2326.
38. Behrend,E.I., Craig,A.M., Wilson,S.M., Denhardt,D.T. and Chambers,A.F. (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res., 54, 832-837.
39. Feng,B., Rollo,E.E. and Denhardt,D.T. (1995) Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin. Exp. Metast., 13, 453-462.
40. Guo,X., Zhang,Y.P., Mitchell,D.A., Denhardt,D.T. and Chambers,A.F. (1995) Identification of a ras-activated enhancer in the mouse osteopontin promoter and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol. Cell. Biol., 15, 476-487.
41. Denhardt,D.T., Mistretta,D., Chambers,A.F., Krishna,S., Porter,J.F., Raghuram,S. and Rittling,S.R. (2003) Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metast., 20, 77-84.
42. Rittling,S.R., Matsumoto,H.N., McKee,M.D., Nanci,A., An,X.R., Novick,K.E., Kowalski,A.J., Noda,M. and Denhardt,D.T. (1998) Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Min. Res., 13, 1101-1111.
43. Sun,Y., Nakamura,K., Hegamyer,G., Dong,Z. and Colburn,N. (1993) No point mutation of Ha-ras or p53 genes expressed in preneoplastic-toneoplastic progression as modeled in mouse JB6 cell variants. Mol. Carcinogen., 8, 49-57.
44. Dong,Z., Birrer,M.J., Watts,R.G., Matrisian,L.M. and Colburn,N.H. (1994) Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. Natl Acad. Sci. USA, 91, 609-613.
45. Young,M.R., Li,J.J., Rincon,M., Flavell,R.A., Sathyanarayana,B.K., Hunziker,R. and Colburn,N. (1999) Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc. Natl Acad. Sci. USA, 96, 9827-9832.
46. O'Brien,T.G., Megosh,L.C., Gilliard,G. and Soler,A.P. (1997) Ornithine decarboxylase overexpression is a sufficient condition for tumor promotion in mouse skin. Cancer Res., 57, 2630-2637.
47. Halmekyto,M., Syrjanen,K., Janne,J. and Alhonen,L. (1992) Enhanced papilloma formation in response to skin tumor promotion in transgenic mice overexpressing the human ornithine decarboxylase gene. Biochem. Biophys. Res. Commun., 187, 493-497.
48. Jansen,A.P., Colburn,N.H. and Verma,A.K. (1999) Tumor promoter-induced ornithine decarboxylase gene expression occurs independently of AP-1 activation. Oncogene, 18, 5806-5813.
49. Colburn,N.H., Bruegge,W.F., Bates,J.R., Gray,R.H., Rossen,J.D., Kelsey,W.H. and Shimada,T. (1978) Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res., 38, 624-634.
50. Smith,J.H. and Denhardt,D.T. (1987) Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. J. Cell. Biochem., 34, 13-22.
51. Craig,A.M., Smith,J.H. and Denhardt,D.T. (1989) Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J. Biol. Chem., 264, 9682-9689.
52. Chang,P.L. and Prince,C.W. (1991) 1 alpha,25-Dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res., 51, 2144-2150.
53. Chang,P.L. and Prince,C.W. (1993) 1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate-induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells. Cancer Res., 53, 2217-2220.
54. Dion,L.D., Gindhart,T.D. and Colburn,N.H. (1988) Four-day duration of tumor promoter exposure required to transform JB6 promotion-sensitive cells to anchorage independence. Cancer Res., 48, 7126-7131.
55. Chang,P.L., Tucker,M.A., Hicks,P.H. and Prince,C.W. (2002) Novel protein kinase C isoforms and mitogen-activated kinase kinase mediate phorbol ester-induced osteopontin expression. Int. J. Biochem. Cell Biol., 34, 1142-1151.
56. Belman,S. and Troll,W. (1972) The inhibition of croton oil-promoted mouse skin tumorigenesis by steroid hormones. Cancer Res., 32, 450-454.
57. Verma,A.K., Garcia,C.T., Ashendel,C.L. and Boutwell,R.K. (1983) Inhibition of 7-bromomethylbenz[a]anthracene-promoted mouse skin tumor formation by retinoic acid and dexamethasone. Cancer Res., 43, 3045-3049.
58. Birt,D.F., Yaktine,A. and Duysen,E. (1999) Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. J. Nutr., 129, 571S-574S.
59. Schwarz,J.A., Viaje,A. and Slaga,J. (1977) Fluocinolone acetonide: a potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem.-Biol. Interact., 17, 331-347.
60. Smith,J.H. and Denhardt,D.T. (1989) Evidence for two pathways of protein kinase C induction of 2ar expression: correlation with mitogenesis. J. Cell. Physiol., 139, 189-195.
61. McGarrity,G.J., Steiner,T. and Vanaman,V. (1983) Detection of mycoplasma infection of cell cultures by DNA fluorochrome staining. In Tully,J.G. and Razin,E. (eds), Methods in Mycoplasmology. Academic Press, New York, Vol. II, pp. 155-208.
62. Lasa,M., Chang,P.L., Prince,C.W. and Pinna,L.A. (1997) Phosphorylation of osteopontin by Golgi apparatus casein kinase. Biochem. Biophys. Res. Commun., 240, 602-605.
63. Ding,Q., Stewart,J.J., Prince,C.W., Chang,P.-L., Trikah,M., Han,X., Grammer,R. and Gladson,C. (2002) Promotion of malignant astrocytoma cell migration by osteopontin expression in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res., 62, 5336-5343.
64. Su,L., Mukherjee,A.B. and Mukherjee,B.B. (1995) Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells: Oncogene, 10, 2163-2169.
65. Chang,P.L., Lee,T.F., Garretson,K. and Prince,C.W. (1997) Calcitriol enhancement of TPA-induced tumorigenic transformation is mediated through vitamin D receptor-dependent and -independent pathways. Clin. Exp. Metast., 15, 580-592.
66. Chang,P.L., Ridall,A.L. and Prince,C.W. (1994) Calcitriol regulation of osteopontin expression in mouse epidermal cells. Endocrinology, 135, 863-869.
67. Zerlauth,G. and Wolf,G. (1985) Release of fibronectin is linked to tumor promotion: response of promotable and non-promotable clones of a mouse epidermal cell line. Carcinog., 6, 73-78.
68. Craig,A.M. and Denhardt,D.T. (1991) The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163-171.
69. Verma,A.K., Conrad,E.A. and Boutwell,R.K. (1980) Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethylben. Carcinogenesis, 1, 607-611.
70. Verma,A.K., Duvick,L. and Ali,M. (1986) Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and alpha-difluoromethyl-ornithine. Carcinogenesis, 7, 1019-1023.
71. Hayman,E.G., Pierschbacher,M.D., Suzuki,S. and Ruoslahti,E. (1985) Vitronectin - a major cell attachment-promoting protein in fetal bovine serum. Exp. Cell. Res., 160, 245-258.
72. Bayless,K.J., Meininger,G.A., Scholtz,M. and Davis,G.E. (1998) Osteopontin is a ligand for the alphavbeta1 integrin. J. Cell Sci., 111, 1165-1174.
73. Isoda,K., Nishikawa,K., Kamezawa,Y., Yoshida,M., Kusuhara,M., Moroi,M., Tada,N. and Ohsuzu,F. (2002) Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ. Res., 91, 77-82.
74. Geissinger,E., Weisser,C., Fischer,P., Schartl,M. and Wellbrock,C. (2002) Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res., 62, 4820-4828.
75. Fedarko,N.S., Fohr,B., Robey,P.G., Young,M.F. and Fisher,L.W. (2000) Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem., 275, 16666-16672